- Home
- /
- News
- /
- Pharmacology/ Therapeutics
- /
- November 2012
Pharmacology/ Therapeutics News for November 2012
Fifty years after scientists first posed a question about protein folding, the search for answers has led to the creation of a full-fledged field of research that led to major advances in supercomputers, new materials and drug discovery, and shaped our understanding of the basic processes of life, including so-called "protein-folding diseases" such as Alzheimer's, Parkinson's and type II diabetes.
27 November, 2012
A*STAR scientists have identified the enzyme, telomerase, as a cause of chronic inflammation in human cancers. Chronic inflammation is now recognized as a key underlying cause for the development of many human cancers, autoimmune disorders, neurodegenerative diseases, and metabolic diseases such as diabetes. This enzyme, which is known to be responsible for providing cancer cells the endless ability to divide, is now found to also jumpstart and maintain chronic inflammation in cancers.
23 November, 2012
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
22 November, 2012
The Myelin Repair Foundation (MRF) has announced the results of a new peer-reviewed research study published in Nature Biotechnology highlighting a targeted, novel approach for multiple sclerosis (MS).
21 November, 2012
A group of researchers at the University of California, Berkeley have for the first time described the structure of the active site core of topoisomerase II alpha, an important target for anticancer drugs.
15 November, 2012
There are plenty of effective anticancer agents around. The problem is that, very often, they cannot gain access to all the cells in solid tumors. A new gene delivery vehicle may provide a way of making tracks to the heart of the target.
14 November, 2012
A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 percent less likely to relapse and around 13 percent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University.
12 November, 2012
Researchers at the University of Illinois at Chicago College of Medicine have developed a transgenic mouse that carries a human gene known to increase risk of Alzheimer's 15-fold. This new mouse mimics the genetics of the human disease more closely than any of the dozen existing mouse models and may prove more useful in the development of candidate drugs to prevent or treat the disease.
09 November, 2012
PharmaInformatic, a German biotech-company has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs.
08 November, 2012
Core research facilities on the Science Exchange network announced today their support for those researchers affected by Hurricane Sandy.
07 November, 2012
Treatment with roflumilast, an orally-administered highly selective phosphodiesterase 4 (PDE4) inhibitor, can help to shift chronic obstructive pulmonary disease (COPD) patients from the frequent to the more stable infrequent exacerbator state, according to a new data analysis published in CHEST.
05 November, 2012
An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.
02 November, 2012